{"schema":"sb.node.v1","id":"sb:e/b98fee0accaf1f85a4fb564a","kind":"entity","label":{"text":"drug development","locale":"en"},"identity":{"anchor":"label:en:drug development","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T13:18:22.628694+00:00","snapshot":"deploy 21a1f50d0f5b421478f518f2cc7cb2b5467baffa"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":287,"separatePublishers":61,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.261: about 74% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma","pharma-regulatory"],"activeDays":58,"assertions":{"regulatory-approval":45,"launch-release":10,"meeting-visit":3,"utterance":3,"legal-ruling":3,"price-threshold":3}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/403644c3bc267430b04570b0","kind":"observation","label":"FDA Drug News · 2026-10-03 · Webinar for Stakeholder Engagement on the New Final Guideline on General Principles for Model-Informed Drug Development (ICH M15) - 10/29/2026","url":"http://www.fda.gov/drugs/news-events-human-drugs/webinar-stakeholder-engagement-new-final-guideline-general-principles-model-informed-drug"},{"id":"sb:o/899475184576477d73414247","kind":"observation","label":"BeBeez International · 2026-09-30 · Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise","url":"https://bebeez.eu/2026/09/30/leads-to-development-joins-clarenta-group-strengthening-early-stage-drug-development-expertise/"},{"id":"sb:o/1771b96c8a69b623a8d53a3d","kind":"observation","label":"FDA · 2026-09-30 · CDER Patient-Focused Drug Development","url":"http://www.fda.gov/drugs/development-approval-process-drugs/cder-patient-focused-drug-development"},{"id":"sb:o/038f2488a8bba3a01eea2e3d","kind":"observation","label":"Peter Attia · 2026-09-28 · #409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.","url":"https://peterattiamd.com/lloydklickstein2/"},{"id":"sb:o/c23de2c0734688b896ac3a8f","kind":"observation","label":"Fierce Biotech · 2026-09-25 · How AI-enabled predictive intelligence is becoming a new advantage in solid tumor drug development","url":"https://www.fiercebiotech.com/resource/how-ai-enabled-predictive-intelligence-becoming-new-advantage-solid-tumor-drug-development"},{"id":"sb:o/4517ff27a128167995163a8a","kind":"observation","label":"FDA · 2026-09-25 · FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds - 08/25/2026","url":"http://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds"},{"id":"sb:o/251a8857b282d26a906d680e","kind":"observation","label":"FDA · 2026-09-24 · Public Meeting on Patient-Focused Drug Development for Long COVID - 04/25/2023","url":"http://www.fda.gov/drugs/news-events-human-drugs/public-meeting-patient-focused-drug-development-long-covid-04252023"},{"id":"sb:o/cfe61131e5f383cdb5081a91","kind":"observation","label":"GEN · 2026-09-23 · Syngene Expands Integrated Drug Development and Manufacturing Services with BMS","url":"https://www.genengnews.com/topics/bioprocessing/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms/"},{"id":"sb:o/c1b7e9756aa5e581aa94a820","kind":"observation","label":"STAT News · 2026-09-23 · STAT+: HHS unveils new initiatives to reduce animal testing in drug development","url":"https://www.statnews.com/pharmalot/2026/09/22/hhs-initiatives-reduce-animal-testing-in-drug-development/?utm_campaign=rss"},{"id":"sb:o/9d0c524a59af5a2bed79b98c","kind":"observation","label":"Veterinary Practice News · 2026-09-23 · FDA updates rules to advance non-animal, innovative testing in human drug development","url":"https://www.veterinarypracticenews.com/fda-updates-rules-advance-non-animal-innovating-testing-drug-development/"}],"cursor":"c1.eyJpZCI6InNiOmUvYjk4ZmVlMGFjY2FmMWY4NWE0ZmI1NjRhIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDEzOjE4OjIyLjYyODY5NCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (139 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fd2ba6b4e454d41e23a64359"},{"kind":"relation","label":"co-mentioned with clinical trials (100 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/60b9fb24eb463403f7625ec4"},{"kind":"relation","label":"co-mentioned with ai (86 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/168524e151b7026b3fef66b4"},{"kind":"relation","label":"co-mentioned with clinical trial (84 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/97b82195e0cc542097031139"},{"kind":"relation","label":"co-mentioned with studie (78 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/40b9e8d1ceb34266ccc00965"},{"kind":"relation","label":"co-mentioned with drug administration (57 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4787133ce9d0291731088cc0"},{"kind":"relation","label":"co-mentioned with cder (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ff9435ce4c29a418cc9b4b4b"},{"kind":"relation","label":"co-mentioned with united states (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/23d6792fcf8b60377ebf459a"},{"kind":"relation","label":"co-mentioned with drug evaluation (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/81bf89d1fe802e49b213061d"},{"kind":"relation","label":"co-mentioned with china (36 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4df1acf6f7ed2a98f3c6add0"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/b98fee0accaf1f85a4fb564a","mcp":"traverse {\"id\":\"sb:e/b98fee0accaf1f85a4fb564a\"}","page":"/entity/drug-development/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b98fee0accaf1f85a4fb564a\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b98fee0accaf1f85a4fb564a\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b98fee0accaf1f85a4fb564a\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b98fee0accaf1f85a4fb564a\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}